Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

420 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Novel antitenascin antibody with increased tumour localisation for Pretargeted Antibody-Guided RadioImmunoTherapy (PAGRIT).
De Santis R, Anastasi AM, D'Alessio V, Pelliccia A, Albertoni C, Rosi A, Leoni B, Lindstedt R, Petronzelli F, Dani M, Verdoliva A, Ippolito A, Campanile N, Manfredi V, Esposito A, Cassani G, Chinol M, Paganelli G, Carminati P. De Santis R, et al. Among authors: paganelli g. Br J Cancer. 2003 Apr 7;88(7):996-1003. doi: 10.1038/sj.bjc.6600818. Br J Cancer. 2003. PMID: 12671694 Free PMC article.
Low and high tenascin-expressing tumors are efficiently targeted by ST2146 monoclonal antibody.
De Santis R, Albertoni C, Petronzelli F, Campo S, D'Alessio V, Rosi A, Anastasi AM, Lindstedt R, Caroni N, Arseni B, Chiodi P, Verdoliva A, Cassani G, Chinol M, Paganelli G, Carminati P. De Santis R, et al. Among authors: paganelli g. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2191-6. doi: 10.1158/1078-0432.CCR-05-2526. Clin Cancer Res. 2006. PMID: 16609034
AvidinOX for highly efficient tissue-pretargeted radionuclide therapy.
De Santis R, Leoni B, Rosi A, Albertoni C, Forni G, Cojoca R, Iezzi M, Musiani P, Paganelli G, Chinol M, Carminati P. De Santis R, et al. Among authors: paganelli g. Cancer Biother Radiopharm. 2010 Apr;25(2):143-8. doi: 10.1089/cbr.2009.0738. Cancer Biother Radiopharm. 2010. PMID: 20423226
Therapeutic use of avidin is not hampered by antiavidin antibodies in humans.
Petronzelli F, Pelliccia A, Anastasi AM, Lindstedt R, Manganello S, Ferrari LE, Albertoni C, Leoni B, Rosi A, D'Alessio V, Deiana K, Paganelli G, De Santis R. Petronzelli F, et al. Among authors: paganelli g. Cancer Biother Radiopharm. 2010 Oct;25(5):563-70. doi: 10.1089/cbr.2010.0797. Epub 2010 Sep 23. Cancer Biother Radiopharm. 2010. PMID: 20863248
Improved tumor targeting by combined use of two antitenascin antibodies.
Petronzelli F, Pelliccia A, Anastasi AM, D'Alessio V, Albertoni C, Rosi A, Leoni B, De Angelis C, Paganelli G, Palombo G, Dani M, Carminati P, De Santis R. Petronzelli F, et al. Among authors: paganelli g. Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7137s-7145s. doi: 10.1158/1078-0432.CCR-1004-0007. Clin Cancer Res. 2005. PMID: 16203813
OXavidin for tissue targeting biotinylated therapeutics.
De Santis R, Albertoni C, Rosi A, Leoni B, Petronzelli F, D'Alessio V, Nucera E, Salvatori G, Paganelli G, Verdoliva A, Carminati P, Nuzzolo CA. De Santis R, et al. Among authors: paganelli g. J Biomed Biotechnol. 2009;2009:921434. doi: 10.1155/2009/921434. Epub 2010 Jan 10. J Biomed Biotechnol. 2009. PMID: 20130784 Free PMC article.
Preclinical pharmacology and safety of a novel avidin derivative for tissue-targeted delivery of radiolabelled biotin.
Petronzelli F, Anastasi AM, Pelliccia A, Santapaola D, Albertoni C, Rosi A, Leoni B, Ferrari LE, Paganelli G, Gramiccioli G, Pesce D, Alfano AM, Stasi MA, De Santis R. Petronzelli F, et al. Among authors: paganelli g. Basic Clin Pharmacol Toxicol. 2011 Sep;109(3):145-55. doi: 10.1111/j.1742-7843.2011.00701.x. Epub 2011 Apr 25. Basic Clin Pharmacol Toxicol. 2011. PMID: 21426491 Free article.
420 results